Persistent infections with specific high-risk human papillomavirus(HR-HPV)strains are the leading cause of cervical cancer and precancerous lesions.HPV-16 and HPV-18 are associated with more than 70%of cervical cancer...Persistent infections with specific high-risk human papillomavirus(HR-HPV)strains are the leading cause of cervical cancer and precancerous lesions.HPV-16 and HPV-18 are associated with more than 70%of cervical cancer.However,with recent widespread vaccination efforts against cervical cancer,the infection rates of HPV-16 and HPV-18 have decreased across all age groups,while the infection rates of other HR-HPV strains have increased.The non-16/18 HR-HPV strains play an important role in cervical lesions.These strains can be identified with extended genotyping,and the 2019 American Society for Colposcopy and Cervical Pathology(ASCCP)guidelines recommended an HPV-based testing to assess the risk of cervical disease in patients.We reviewed and analyzed the clinical benefits of applying extended HR-HPV genotyping,which was published by the International Agency for Research on Cancer(HPV-16,18,31,33,35,39,45,51,52,56,58,59,66,and 68),to cervical cancer screening.This review concluded that cervical cancer screening needs to include extended HR-HPV genotyping.The examination of extended HR-HPV genotyping in cervical intraepithelial lesions and cervical cancers can help guide clinical practices.展开更多
Trichomoniasis and HPV infection are common non-viral and viral sexually transmitted diseases worldwide.Emerging evidence shows that the female genital tract and its microbiota are greatly affected by these pathogens....Trichomoniasis and HPV infection are common non-viral and viral sexually transmitted diseases worldwide.Emerging evidence shows that the female genital tract and its microbiota are greatly affected by these pathogens.However,the relationship between Trichomonas vaginalis,the vaginal microbiome,and High-risk(HR)-HPV infection is complex and multifaceted.Studies have proven that concurrent infections of HIV and HPV increase the risk of cervical cancer.With this basis,a question arises:How does the concurrent infection of trichomonas vaginalis and HPV affect genital tract health?Does this concurrent infection enhance or inhibit the development of cervical lesions?This review aims to bring light to these questions.This review also covers the association of trichomonas vaginalis and HPV with the microbiota of the genital tract.展开更多
More and more molecular drugs based on targeted therapy have been utilized in the treatment of gynecologic cancer,especially in ovarian cancer.In this article,we systematically review the current targeted therapeutic ...More and more molecular drugs based on targeted therapy have been utilized in the treatment of gynecologic cancer,especially in ovarian cancer.In this article,we systematically review the current targeted therapeutic trials running in clinic.Large,randomized trials have been conducted in the treatment of ovarian cancer,endometrial cancer and cervical cancer by using small molecule,antisense,mutational gene as well as antibodies.Other planned or ongoing trials currently targeted at molecular markers which may play important roles in gynecological carcinogenesis and progression suggest that combination chemotherapy with molecular targeted therapy will ultimately be an important option.展开更多
基金the Fund of National Key R&D Program of China(Grant no.2021YFC2701205)the National Nature Science Foundation of China(Grant no.82271658)Major scientific research projects of young and middle-aged people of Fujian Provincial Health Commission(grant no.2021ZQNZD011).
文摘Persistent infections with specific high-risk human papillomavirus(HR-HPV)strains are the leading cause of cervical cancer and precancerous lesions.HPV-16 and HPV-18 are associated with more than 70%of cervical cancer.However,with recent widespread vaccination efforts against cervical cancer,the infection rates of HPV-16 and HPV-18 have decreased across all age groups,while the infection rates of other HR-HPV strains have increased.The non-16/18 HR-HPV strains play an important role in cervical lesions.These strains can be identified with extended genotyping,and the 2019 American Society for Colposcopy and Cervical Pathology(ASCCP)guidelines recommended an HPV-based testing to assess the risk of cervical disease in patients.We reviewed and analyzed the clinical benefits of applying extended HR-HPV genotyping,which was published by the International Agency for Research on Cancer(HPV-16,18,31,33,35,39,45,51,52,56,58,59,66,and 68),to cervical cancer screening.This review concluded that cervical cancer screening needs to include extended HR-HPV genotyping.The examination of extended HR-HPV genotyping in cervical intraepithelial lesions and cervical cancers can help guide clinical practices.
文摘Trichomoniasis and HPV infection are common non-viral and viral sexually transmitted diseases worldwide.Emerging evidence shows that the female genital tract and its microbiota are greatly affected by these pathogens.However,the relationship between Trichomonas vaginalis,the vaginal microbiome,and High-risk(HR)-HPV infection is complex and multifaceted.Studies have proven that concurrent infections of HIV and HPV increase the risk of cervical cancer.With this basis,a question arises:How does the concurrent infection of trichomonas vaginalis and HPV affect genital tract health?Does this concurrent infection enhance or inhibit the development of cervical lesions?This review aims to bring light to these questions.This review also covers the association of trichomonas vaginalis and HPV with the microbiota of the genital tract.
基金supported by the National Natural Science Foundation of China(Grant No.30600666)Karl-Daimler Benz research foundation(No.17-05/03)+1 种基金Science and Technology Research Foundation of Fujian Province(No.2008I00011)this article was presented in the 3rd Conference of Molecular Biological Therapy Target on Gynecologic Oncology,NOGGO.
文摘More and more molecular drugs based on targeted therapy have been utilized in the treatment of gynecologic cancer,especially in ovarian cancer.In this article,we systematically review the current targeted therapeutic trials running in clinic.Large,randomized trials have been conducted in the treatment of ovarian cancer,endometrial cancer and cervical cancer by using small molecule,antisense,mutational gene as well as antibodies.Other planned or ongoing trials currently targeted at molecular markers which may play important roles in gynecological carcinogenesis and progression suggest that combination chemotherapy with molecular targeted therapy will ultimately be an important option.
